张静瑜, 吕丹丹, 谢燕东. 雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察[J]. 实用临床医药杂志, 2020, 24(16): 43-46. DOI: 10.7619/jcmp.202016012
引用本文: 张静瑜, 吕丹丹, 谢燕东. 雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察[J]. 实用临床医药杂志, 2020, 24(16): 43-46. DOI: 10.7619/jcmp.202016012
ZHANG Jingyu, LYU Dandan, XIE Yandong. Effect observation of rabeprazole combined with mosapride in treatment of patients with functional dyspepsia[J]. Journal of Clinical Medicine in Practice, 2020, 24(16): 43-46. DOI: 10.7619/jcmp.202016012
Citation: ZHANG Jingyu, LYU Dandan, XIE Yandong. Effect observation of rabeprazole combined with mosapride in treatment of patients with functional dyspepsia[J]. Journal of Clinical Medicine in Practice, 2020, 24(16): 43-46. DOI: 10.7619/jcmp.202016012

雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察

Effect observation of rabeprazole combined with mosapride in treatment of patients with functional dyspepsia

  • 摘要: 目的 观察雷贝拉唑联合莫沙必利治疗功能性消化不良(FD)的临床疗效。 方法 将152例FD患者按简单随机数字表法分为对照组和联合组,每组76例。对照组给予促胃肠动力药物莫沙必利治疗,联合组给予雷贝拉唑联合莫沙必利方案治疗,均持续治疗6周。比较2组治疗前后胃肠排空率变化、不良反应发生率。治疗后通过门诊和电话等形式随访6个月,观察2组FD复发情况。 结果 治疗6周后, 2组胃、肠排空率均较治疗前提高,且联合组高于对照组,差异有统计学意义(P<0.05)。联合组临床总有效率为90.79%, 高于对照组的77.63%, 差异有统计学意义(P<0.05)。2组随访3个月FD复发率比较,差异无统计学意义(P>0.05)。随访6个月联合组FD复发率为7.25%, 低于对照组的20.34%, 差异有统计学意义(P<0.05)。 结论 雷贝拉唑联合莫沙必利能显著提高FD患者胃肠排空率,降低复发率,且联合用药不良反应发生率无明显增加。

     

    Abstract: Objective To explore the clinical effect of rabeprazole combined with mosapride in the treatment of functional dyspepsia(FD). Methods A total of 152 FD patients were divided into control group and combination group according to simple random number table method, with 76 cases in each group. The control group was treated with the gastrointestinal motile drug mosapride, and the combined group was treated with rabeprazole combined with mosapride regimen for 6 weeks. The changes of gastrointestinal drainage rate and adverse reaction rate before and after treatment were compared between the two groups. After treatment, outpatient and telephone follow-up were conducted for 6 months, and the recurrence of FD was observed in the two groups. Results After 6 weeks of treatment, the rates of gastric and intestinal drainage in both groups were significantly higher than those before treatment, and the combined group was significantly higher than those in the control group(P<0.05). The total clinical response rate of the combined group was 90.79%, which was significantly higher than 77.63% in the control group(P<0.05). There was no significant difference in FD recurrence rate between the two groups after 3-month follow-up(P>0.05). The recurrence rate of FD after 6-month follow-up in the combined group was 7.25%, which was significantly lower than 20.34% in the control group(P<0.05). Conclusion Rabeprazole combined with mosapride can significantly improve the gastrointestinal emptying rate and reduce the recurrence rate of FD, and the combination of drugs does not significantly increase adverse reactions.

     

/

返回文章
返回